Quantity
Single
Pack of 3
Pack of 6
Retatrutide
Order Now, Ships Today
$230
One-time
Add To Cart
Research Use Only
Research Use Only - All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
Certificate of Analysis
Certificate of Analysis - Third-party tested for 99% purity, ID, quantity.
Retatrutide
Overview
Retatrutide (LY3437943) is a synthetic peptide that functions as a triple agonist, targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This compound was developed by Eli Lilly for the potential treatment of obesity and type 2 diabetes. Its molecular formula is C221H342N46O68, with a molecular weight of 4731.5 g/mol. Research indicates its activity across multiple metabolic pathways.
Coskun T. et al. (2022).
History
LY3437943 emerged from efforts to develop multireceptor agonists for metabolic health. Early preclinical studies investigated its pharmacology and mechanism of action, demonstrating superior body weight loss in obese mice compared to other treatments. A phase 1 clinical trial established its safety, tolerability, and pharmacokinetic profile, supporting once-weekly dosing. These initial findings provided the foundation for further clinical assessment in humans.
Coskun T. et al. (2022).
Retatrutide
Structure
Molecular Formula:
C221H342N46O68
Molecular Weight:
4731.5 g/mol
PubChem ID:
171390338
Research Findings
Retatrutide has been studied in clinical trials for its effects on body weight and glycemic control in individuals with obesity and type 2 diabetes. Studies have reported significant reductions in body weight and improvements in metabolic outcomes. Its triple agonist activity contributes to these effects by influencing energy expenditure and glucose homeostasis.
Key Areas of Research:
Metabolic: Glucose, insulin, lipid regulation
Weight Management: Body weight reduction, energy expenditure
Endocrine: Incretin hormone signaling, glucagon modulation
Clinical Outcomes: Glycemic control, cardiovascular markers
These findings suggest that retatrutide holds promise as a potent therapeutic agent for managing obesity and related metabolic disorders. Continued research aims to further elucidate its long-term efficacy and safety profile across diverse patient populations.
Our Process
Text us, our dedicated team is here to help
Reach out and get a response within minutes.
Frequently Asked Questions
All products are for research use only. Third-party testes for 99%+ purity.
